TEDCO Invests in BC3 Technologies

Maryland-based MedTech company works to expand emergency preparedness through lifesaving innovation

COLUMBIA, Md., (July 15, 2026) - TEDCO, Maryland's economic engine for technology companies, announced a recent $200,000 Pre-Seed Builder Fund ("Builder Fund") investment in BC3 Technologies, a Baltimore-based, minority-owned medical technology company developing emergency preparedness and hemorrhage control technologies designed to help save lives before professional medical care arrives.

"With more than 200,000 Americans succumbing to trauma-related fatalities each year, it was clear that something needed to be done," said BC3 Technologies' CEO Wayne Grube, Jr. "We saw an opportunity to develop technology that helps bridge the gap between injury and professional medical care. With TEDCO's investment, we will continue our growth, enhance research and product development, and advance our mission of making lifesaving technology more accessible to first responders, workplaces, families, military and communities around the world. I would encourage entrepreneurs in Maryland to explore everything TEDCO has to offer."

Founded in Baltimore, BC3 Technologies is a medical technology company developing innovation in emergency preparedness, emergency medical response and hemorrhage control. Its SEAL Hemostatic Wound Spray is an FDA-cleared aerosolized hemostatic wound spray, designed to help control severe external bleeding for both trained professionals and everyday citizens.

"The innovative solution BC3 Technologies is offering has the potential to help people across the world-both civilian and military," said Jean-Luc Park, deputy chief investment officer & senior director of Social Impact Funds. "TEDCO looks forward to seeing the company's development with this investment."

Resting under the Social Impact Funds umbrella, the Builder Fund was created to open opportunities for technology and life sciences-based entrepreneurs who are traditionally overlooked. Pairing funding with hands-on support, companies invested in are given access to mentorship, operational guidance and TEDCO's statewide network, helping founders navigate early growth while preparing for future investment.

"With a life sciences industry generating $18.6 billion in economic activity, it is no surprise that Maryland is home to the third ranking biopharma cluster in the nation," said TEDCO CEO Troy LeMaile-Stovall. "The state is a premier location for life sciences companies, offering strategic proximity to federal institutions, top ranking universities and more; any entrepreneur looking to grow in the life sciences industry should strongly consider all that Maryland has to offer."

For more information about TEDCO funding opportunities, visit our page at tedcomd.com.